JP5805880B2 - 1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)−プロパ−2−エン−1−オン塩酸塩の製造方法および該方法で用いられる中間体 - Google Patents

1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)−プロパ−2−エン−1−オン塩酸塩の製造方法および該方法で用いられる中間体 Download PDF

Info

Publication number
JP5805880B2
JP5805880B2 JP2014534478A JP2014534478A JP5805880B2 JP 5805880 B2 JP5805880 B2 JP 5805880B2 JP 2014534478 A JP2014534478 A JP 2014534478A JP 2014534478 A JP2014534478 A JP 2014534478A JP 5805880 B2 JP5805880 B2 JP 5805880B2
Authority
JP
Japan
Prior art keywords
formula
compound
group
mixtures
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014534478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528444A (ja
Inventor
パン・グクチャン
ムン・ヨンホ
チャン・ヨンキル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5805880(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of JP2014528444A publication Critical patent/JP2014528444A/ja
Application granted granted Critical
Publication of JP5805880B2 publication Critical patent/JP5805880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014534478A 2011-10-05 2012-10-05 1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)−プロパ−2−エン−1−オン塩酸塩の製造方法および該方法で用いられる中間体 Expired - Fee Related JP5805880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0101422 2011-10-05
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
PCT/KR2012/008077 WO2013051883A2 (en) 2011-10-05 2012-10-05 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein

Publications (2)

Publication Number Publication Date
JP2014528444A JP2014528444A (ja) 2014-10-27
JP5805880B2 true JP5805880B2 (ja) 2015-11-10

Family

ID=48044309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534478A Expired - Fee Related JP5805880B2 (ja) 2011-10-05 2012-10-05 1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)−プロパ−2−エン−1−オン塩酸塩の製造方法および該方法で用いられる中間体

Country Status (23)

Country Link
US (1) US8859767B2 (enExample)
EP (2) EP3611172A1 (enExample)
JP (1) JP5805880B2 (enExample)
KR (1) KR101272613B1 (enExample)
CN (2) CN110003174A (enExample)
AU (1) AU2012319291B2 (enExample)
BR (1) BR112014007718B1 (enExample)
CA (1) CA2850055C (enExample)
CY (1) CY1122758T1 (enExample)
DK (1) DK2763981T3 (enExample)
ES (1) ES2775197T3 (enExample)
HR (1) HRP20200426T1 (enExample)
HU (1) HUE048798T2 (enExample)
IL (3) IL231911B (enExample)
IN (1) IN2014DN03447A (enExample)
LT (1) LT2763981T (enExample)
MX (1) MX348815B (enExample)
PL (1) PL2763981T3 (enExample)
PT (1) PT2763981T (enExample)
RS (1) RS60118B1 (enExample)
RU (1) RU2563630C1 (enExample)
SI (1) SI2763981T1 (enExample)
WO (1) WO2013051883A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
JP6704422B2 (ja) 2015-03-20 2020-06-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. キナゾリン誘導体の塩およびその製造方法
KR102802129B1 (ko) * 2018-09-14 2025-05-02 한미약품 주식회사 퀴나졸린 화합물 및 이의 염산염의 결정 형태
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
WO2022043923A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
JP2009518450A (ja) * 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US8450482B2 (en) * 2009-04-23 2013-05-28 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline

Also Published As

Publication number Publication date
HUE048798T2 (hu) 2020-08-28
EP2763981A2 (en) 2014-08-13
LT2763981T (lt) 2020-05-25
ES2775197T3 (es) 2020-07-24
DK2763981T3 (da) 2020-03-16
JP2014528444A (ja) 2014-10-27
EP2763981B1 (en) 2020-01-08
CN103857672B (zh) 2018-11-30
WO2013051883A2 (en) 2013-04-11
CA2850055E (en) 2013-04-11
EP2763981A4 (en) 2015-02-25
CA2850055C (en) 2016-05-17
US20140275534A1 (en) 2014-09-18
CA2850055A1 (en) 2013-04-11
IL231911A0 (en) 2014-05-28
US8859767B2 (en) 2014-10-14
IN2014DN03447A (enExample) 2015-06-26
CN110003174A (zh) 2019-07-12
BR112014007718A2 (pt) 2017-04-25
RS60118B1 (sr) 2020-05-29
PT2763981T (pt) 2020-03-25
PL2763981T3 (pl) 2020-08-10
RU2563630C1 (ru) 2015-09-20
EP3611172A1 (en) 2020-02-19
IL259694A (en) 2018-07-31
BR112014007718B1 (pt) 2022-02-22
CY1122758T1 (el) 2021-03-12
MX2014003959A (es) 2014-05-14
CN103857672A (zh) 2014-06-11
IL291738A (en) 2022-05-01
WO2013051883A3 (en) 2013-06-06
IL231911B (en) 2018-06-28
HRP20200426T1 (hr) 2020-09-04
SI2763981T1 (sl) 2020-07-31
KR20130037079A (ko) 2013-04-15
KR101272613B1 (ko) 2013-06-10
AU2012319291A1 (en) 2014-05-22
IL259694B (en) 2022-04-01
MX348815B (es) 2017-06-30
AU2012319291B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JP5805880B2 (ja) 1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)−プロパ−2−エン−1−オン塩酸塩の製造方法および該方法で用いられる中間体
KR101342241B1 (ko) 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온 화합물의 제조 방법
JP7377307B2 (ja) 1-(4-(4-(3,4-ジクロロ-2-フルオロフェニルアミノ)-7-メトキシキナゾリン-6-イルオキシ)ピペリジン-1-イル)プロパ-2-エン-1-オンの製造方法
EP2608791B1 (en) A process for the preparation of imatinib base
EP2509973A1 (en) Process for the preparation of imatinib and salts thereof
HK40010388A (en) Preparation method for hydrochloride compound
HK1196132A (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein
KR102204267B1 (ko) 대체된 (r)-3-(4-메틸카바모일-3-플루오로페닐아미노)테트라하이드로퓨란-3-엔카르복실산(변이체) 및 이의 에스테르, 제조 방법 및 용도
JP6030644B2 (ja) 置換されたフェニル化合物
KR101116754B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 6-아미노-ν-하이드록시헥산아마이드 화합물 및 이의 제조방법
HK1196132B (zh) 用於制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150902

R150 Certificate of patent or registration of utility model

Ref document number: 5805880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees